CytoMed Therapeutics GDTC · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.86

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SGD, from our data supplier.

FY2025

Revenue

SGD 319,201

FY2019FY2025

Net income

−SGD 3.9m

FY2019FY2025

Free cash flow

−SGD 4.4m

FY2019FY2025

Shareholders' equity

SGD 6.5m

FY2019FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	SGD 319,201	SGD 69,501	SGD 509,125	SGD 365,604	SGD 84,178	SGD 44,923	—
Research and development	SGD 2.2m	SGD 1.9m	SGD 1.6m	SGD 1.5m	SGD 1.1m	SGD 1.0m	SGD 439,796
Operating income	−SGD 4.5m	−SGD 3.1m	−SGD 1.6m	−SGD 2.3m	−SGD 1.2m	−SGD 1.3m	−SGD 651,880
Net income	−SGD 3.9m	−SGD 2.5m	−SGD 4.1m	−SGD 3.1m	−SGD 2.1m	−SGD 1.9m	−SGD 858,748
Diluted earnings per share	-0.33	-0.22	-0.36	-0.28	-0.28	-0.33	-0.07

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Total assets	SGD 8.0m	SGD 10.1m	SGD 12.4m	SGD 5.3m	SGD 6.1m	SGD 3.8m	SGD 2.9m
Cash and short-term investments	SGD 2.1m	SGD 5.0m	SGD 9.0m	SGD 1.6m	SGD 2.5m	SGD 930,810	SGD 459,222
Total liabilities	SGD 1.1m	SGD 1.0m	SGD 1.1m	SGD 4.7m	SGD 3.5m	SGD 3.3m	SGD 1.0m
Debt	SGD 482,562	SGD 463,147	SGD 449,247	SGD 4.2m	SGD 3.3m	SGD 3.0m	SGD 674,609
Shareholders' equity	SGD 6.5m	SGD 9.0m	SGD 11.3m	SGD 589,712	SGD 2.6m	SGD 477,015	SGD 1.9m
Shares outstanding	12m	12m	12m	11m	7m	6m	12m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Cash from operations	−SGD 3.7m	−SGD 2.7m	−SGD 3.5m	−SGD 1.4m	−SGD 1.7m	−SGD 916,395	−SGD 640,517
Capital spending	−SGD 703,134	−SGD 1.4m	−SGD 58,454	−SGD 475,999	−SGD 583,715	−SGD 245,263	−SGD 1.2m
Free cash flow	−SGD 4.4m	−SGD 4.1m	−SGD 3.6m	−SGD 1.9m	−SGD 2.3m	−SGD 1.2m	−SGD 1.8m

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	-4.4%	48.0%	—
Operating income	25.6%	27.8%	—
Net income	8.6%	15.1%	—

Average margins

Over each period

	1 year	3 years	5 years	10 years
Operating margin	-1968.2%	-911.2%	-1005.1%	—
Net margin	-1655.1%	-1079.1%	-1267.4%	—

Valuation history

At each fiscal year end

	FY2025
Price to earnings	-4.0
Price to sales	49.3

Share price return

Finished calendar years

	2025
Return	-55%

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

CytoMed Therapeutics GDTC · USD

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Growth per year

Average margins

Valuation history

Share price return

Sources and methodology